Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Commented on a SA article on Neulasta biosimilars. Of course it didn't mention Rolontis and I felt compelled to comment

I’d be remis if I didn’t point out to your readers that one thing your article didn’t mention is that there’ll also be another drug, in addition to the biosimilars you mention, that will be competing in the Neulasta space next year that will be capturing a chunk of the market, and that is Rolontis from Spectrum Pharmaceuticals. Rolontis (eflapegrastim) is a novel, long-acting granulocyte colony-stimulating factor (G-CSF) that utilizes a propriety technology different than Neulasta. Rolontis clinical testing includes one Phase 2 and two Phase 3 clinical studies involving approximately 800 patients, and unlike the Neulasta biosimilars, it has been tested for efficacy against Neulasta, and will compete on its own merits against Neulasta and any Neulasta biosimilars. Spectrum will be submitting their BLA in the 4th quarter. Here’s the link to Spectrum’s PR about their abstract at ASCO 2018

http://investor.sppirx.com/news-releases/news-release-details/correcting-and-replacing-spectrum-pharmaceuticals-announces

Here's the link to the Seeking Alpha article
https://seekingalpha.com/article/4179076-mylan-coherus-play-upcoming-neulasta-biosimilar-race?dr=1